WOUNDCARE FUND — WEEKLY PERFORMANCE SNAPSHOT
WoundCare Fund: +6.68% NASDAQ: +4.98% | S&P 500: +2.81% | Dow Jones: +0.71%
The WoundCare Fund closed the week up +6.68%, surpassing even a strong broader market. The NASDAQ Composite surged 5.19%, the S&P 500 gained +2.95%, and the Dow added +0.79%. Risk-on week. And wound care showed up.
Key Movers — Upside
Avita Medical — +34.14% Likely driven by a combination of commercial momentum and renewed confidence in RECELL adoption across burn and soft tissue applications — with the Cohealyx interim data landing at ABA as a meaningful catalyst. When utilization signals turn positive, this name tends to re-rate quickly and aggressively.
Treace Medical Concepts — +31.69% After prior pressure, this looks like a sharp rebound driven by stabilization in procedure growth expectations. Investors appear to be reassessing the durability of the Lapiplasty platform and its long-term position in the bunion correction market.
Spectral AI — +29.45% Continued momentum reflects growing interest in AI-driven wound diagnostics. As clinical validation and commercialization pathways become clearer, investors are leaning into the measure/assess category as a next wave of innovation.
Tela Bio — +28.07%
This kind of move typically signals a shift in confidence around revenue growth and adoption of its OviTex platform. Likely drivers include improving procedure volumes in hernia and abdominal wall reconstruction, alongside signs of operating leverage. Small-cap soft tissue reconstruction names can re-rate quickly when the market sees a clearer path to scale—and this week looked like one of those moments.
OPENING SHOT
SAWC Week Is in the Books. The Data Is Starting to Land. And AI Just Got a New Regulatory Map.
SAWC Spring 2026 wrapped in Charlotte last week — and for anyone paying attention, the floor told a story. Clinical data was front and center: enzymatic debridement, biofilm disruption, wound bed preparation, and AI-assisted diagnostics all drew real crowds and real conversations. The 2026 agenda featured more than 80 sessions and 25+ CME/CE credits across chronic wound management, diabetic foot, pressure injury, and emerging science — and the WCCC Summit brought FDA and CMS into the room with industry in a format that felt less like a policy briefing and more like a negotiation.
Post-SAWC, the signal feed is busy. AVITA Medical dropped Cohealyx interim data the same week. MediWound published U.S. expert consensus supporting EscharEx. Kane Biotech presented revyve pH-normalization data at the conference. And the FDA's evolving stance on AI/SaMD regulation is clarifying in ways that matter to every diagnostics and digital workflow company in this market.
The week's data didn't all point in the same direction — but the direction of travel is clear. Clinical evidence is the currency. Companies building it are pulling ahead.
NEW | BTK CAPITAL SIGNAL — Q1 2026 Introducing BTK's Quarterly Read on Where the Money Is Moving
This quarter, BTK launches a new standing resource: the BTK Capital Signal — a quarterly narrative report tracking capital flow, M&A activity, and investment trends across the wound care, limb salvage, vascular intervention, and foot and ankle market.
No paywalls. No subscriptions. Free to download at belowtheknee.co/capital-signal.
The Q1 2026 edition is live now. Here's what the data is telling us:
The CAMP reimbursement reset is restructuring capital decisions, not just revenue lines. The 2026 adjustment to $127.28 per cm² — a 12% reduction from 2025 levels — is showing up directly in M&A valuations and commercial strategy conversations. Companies that built around prior reimbursement assumptions are being repriced in real time.
Strategic buyers dominated Q1 M&A. 73% of BTK-adjacent deals in Q1 involved strategic acquirers rather than financial sponsors. That's consolidation logic, not financial engineering. Reimbursement pressure and the demand for integrated solutions are driving it.
Early-stage capital is outpacing late-stage by more than 2x. Series A–B activity ran 2.3x higher than late-stage funding. Investors are looking for differentiated platforms that can navigate the new payer environment — not incremental improvements on existing technology.
Commercial and reimbursement talent is the new strategic asset. Job postings for commercial and reimbursement roles increased 156% year-over-year. The companies that understand where competitive advantage now lives are hiring accordingly.
International expansion is accelerating. European and APAC market entries increased 41% in Q1. When domestic reimbursement tightens, the smart money diversifies its revenue geography.
The full Q1 analysis — including category-level breakdowns, deal analysis, and the BTK read on what it all means — available now as a free resource for you.
WOUND CARE
Clinical | AVITA Medical's Cohealyx Cuts Time to Grafting by Nearly 20 Days
AVITA Medical (NASDAQ: RCEL) announced positive interim results from its Cohealyx-I multi-center study showing a reduction of nearly 20 days in mean time to skin grafting — 13.6 days versus a 33.2-day real-world benchmark BioSpace for patients with full-thickness wounds. The interim analysis of 40 patients demonstrated a median time to grafting of 11 days, with grafting achieved as early as 5 days. Investigators reported 90% satisfaction at the time of grafting National Today, including among predominantly first-time users — a meaningful adoption signal. Data was presented at an AVITA symposium on April 15, during the American Burn Association Annual Meeting. The full dataset is expected later in 2026.
The BTK read: This is the data point AVITA needed. A ~20-day reduction in time to grafting doesn't just improve patient outcomes — it changes the resource calculus in burn and acute wound centers. Ninety percent investigator satisfaction in a predominantly first-time user cohort is the kind of number that drives formulary conversations. The stock moved accordingly: +34.68% on the week. Watch for the full dataset.
Clinical | MediWound Highlights U.S. Expert Consensus Supporting EscharEx® Strategy
A peer-reviewed supplement published in WOUNDS — titled "Toward a Practical Framework for Debridement in Chronic Wounds: Findings From a United States-Based Multidisciplinary Consensus Panel" — redefines debridement as a biologically active intervention that drives wound healing, rather than simply the removal of non-viable tissue. The consensus noted that no single current treatment addresses all clinical needs, and highlighted the importance of flexible treatment strategies — supporting the need for advanced therapies that provide rapid outcomes without surgical intervention. The panel explicitly supports early use of effective, less invasive approaches — the clinical positioning EscharEx® is designed to occupy. The global Phase III VALUE trial in venous leg ulcers is underway, with an interim analysis expected in mid-2026, and clinical studies in diabetic foot ulcers and pressure ulcers planned for the second half of the year.
The BTK read: Consensus publications are not just academic exercises — they shape treatment protocols, payer criteria, and the questions clinicians ask at the bedside. A multidisciplinary U.S. panel elevating enzymatic debridement as a preferred first-line approach is market infrastructure being built in real time. MediWound's +15% week reflects that the market is paying attention. The VALUE interim in mid-2026 is the next hard catalyst.
People | Spectral AI Appoints David McGuire as Chief Financial Officer
Spectral AI (Nasdaq: MDAI) announced the appointment of David McGuire, CPA, as Chief Financial Officer, effective May 4, 2026. McGuire brings more than 20 years of finance and accounting experience, including prior roles as Chief Accounting Officer at Solo Brands and Deputy CFO at EZCORP. He began his career at Ernst & Young, where he spent 14 years. CEO Vincent Capone framed the hire explicitly around commercial readiness: the appointment is described as preparation for commercialization of the DeepView® System.
The BTK read: The CFO hire is a signal, not a footnote. When a company at Spectral AI's stage brings in a seasoned public company finance executive — one with capital markets experience and a background scaling public company infrastructure — it typically means the commercial story is getting closer to requiring that infrastructure. DeepView is an AI-assisted wound assessment platform with meaningful clinical validation behind it. The question has always been: when does it become a revenue event? This hire suggests the team is treating that question as near-term, not hypothetical. The +18.49% week reflects that the market agrees.
Clinical | Kane Biotech Presents Revyve® pH-Normalization Data at SAWC
Kane Biotech (TSX-V: KNE) presented at SAWC Spring 2026 in Charlotte, sharing case study data on how revyve can convert complex chronic non-healing wounds. Mechanistic investigations showed that chronic wound average pH dropped from 8.0 to 6.8 over four weeks, with an associated 45% average wound size reduction in two patients, and a 60% wound size reduction in one week in a third patient. The presentation also included a case study of a patient with venous leg ulcers spanning more than 20 years and a combined wound size exceeding 120 cm².
The BTK read: The pH angle is underappreciated in the broader wound care conversation. Chronic wound environments are alkaline — normal skin pH is slightly acidic, and non-healing wounds diverge significantly from that baseline. If revyve can reliably normalize wound pH as a mechanism, that's a differentiated story that doesn't require head-to-head competition with the major biologics. Still early-stage evidence, but the data trend is pointed in the right direction.
Commercial | Covalon Reports Milestones Across Vascular Access, Infection Prevention, and Wound Care
Covalon Technologies (TSX: COV; OTCQX: CVALF) reported strong commercial momentum across its vascular access and wound care portfolio following a productive week at the Infusion Nurses Society Annual Meeting — and announced that the topic of IV line connection contamination has been selected as part of the official education programs at both the APIC Annual Conference in June and the AVA Annual Scientific Meeting in October. The company views inclusion in three of the most influential infection prevention and vascular access gatherings as validation of its emerging leadership in the space. On the wound care side, a scientific poster by wound care KOL Dr. Traci Kimball was presented at SAWC, detailing results achieved with Covalon's patented collagen matrix dressing in accelerating healing in complex wound environments.
The BTK read: Covalon is playing a longer game than its market cap suggests. The conference education strategy — getting IV line contamination onto the podium at INS, APIC, and AVA in the same year — is how you build a clinical franchise before you've built a commercial one. The SAWC poster is the wound care thread in a multi-channel clinical presence push. Worth monitoring as the BD discussions referenced in recent filings mature.
Regulatory | FDA's AI/SaMD Regulatory Posture Is Shifting — Here's What It Means for BTK
The FDA's January 2026 guidance updates on Clinical Decision Support Software and General Wellness Devices represent the most significant shift in digital health regulation in several years. FDA Commissioner Makary announced the changes at CES, stating that FDA needs to "adapt with the times," and that the updates promote innovation and capital investment in AI and digital wearable technologies. The 2026 CDS guidance places greater emphasis on transparency regarding data inputs, underlying logic, and how recommendations are generated — particularly for algorithmic or AI-driven CDS, reflecting increased FDA attention to automation bias and how clinicians interpret software outputs.
For the BTK market specifically: wound assessment, spectral imaging, and AI-assisted documentation platforms operating at the clinical decision support layer now have materially clearer regulatory lanes. Companies like Spectral AI, Swift Medical, and others building SaMD into wound care workflows have a more defined path than they did 12 months ago. That clarity has value — in product roadmaps, in investor conversations, and in hospital procurement processes.
➡ Why It Matters: Regulatory ambiguity is not a neutral condition — it delays investment, slows adoption, and increases commercial friction. The January 2026 guidance change is a meaningful tailwind for the diagnostics and AI-assisted wound care segment. It won't move stock prices on its own, but it removes a structural headwind that has been present for years.
SAWC SPRING 2026 — WHAT WE HEARD FROM THE FLOOR
Charlotte wrapped on April 12. Here's the BTK read on the week.
The conference felt different this year. The first major gathering of the wound care industry since the CMS December 2024 restructuring fully activated, SAWC 2026 was less about product launches and more about positioning. Companies came with clinical data or they came on defense. The difference was visible.
Debridement dominated the clinical conversation. Based on attendee evaluations identifying debridement as one of the most requested topics, SAWC added a plenary session — "The Art and Science of Debridement: A Multi-Disciplinary Approach" — on April 12. That's a program committee responding to real demand. MediWound had data on EscharEx. Kane Biotech had revyve data. The enzymatic category is generating more clinical attention than it has in years — and SANTYL's dominance as the default is being questioned in a way that feels substantive rather than promotional.
The WCCC Summit was the room to be in. Through dialogue with FDA and CMS, patient-centered evidence discussions, digital innovation insights, and stakeholder-driven collaboration, the Summit strengthened the foundation for progress across the wound care ecosystem. The presence of regulatory leadership alongside commercial and clinical stakeholders in a structured working session format is exactly the kind of mechanism that produces actionable policy outcomes rather than conference theater.
AI was everywhere, but the questions are getting harder. The diagnostics and imaging category drew real traffic on the floor. But the questions from clinicians have evolved — from "what does this do?" to "how does it integrate with my workflow?" and "what does the payer cover?" That's progress. It's also a signal that companies in this category need to be further along on the reimbursement and integration story than they might have been two years ago.
The post-CMS restructuring filter held. Companies with diversified channels, clinical evidence, and a clear reimbursement thesis were having different conversations than the ones that weren't. That divergence — previewed in the Q4 earnings cycle — was visible on the floor in Charlotte.
📅 UPCOMING EVENTS
May 1–2 | Republic of Maldives 4th D-Foot International Wound Conference D-Foot International's global diabetic foot conference. International faculty, keynotes, workshops, and live demonstrations. Worth tracking as a signal of diabetic foot care education expanding well beyond traditional conference geographies.
May 6–8 | Bremen, Germany 🔥 EWMA-DEWU 2026 — Messe Bremen The 36th European Wound Management Association Congress, co-hosted with the German Wound Congress. 5,000+ international attendees, 150+ exhibitors. Sessions spanning AI, diabetic foot, antimicrobial stewardship, and compression therapy. The must-attend European wound care event of 2026.
May 14–15 | Austin, TX 🔥 Advanced Wound Care Summit (AWCS) — Marriott Downtown Organized by Kernexus in partnership with SmartTRAK. Dedicated to the business of wound care — investors, startups, multinationals, payors, distributors, CROs, OEMs, regulators. Sessions include CAMP company diversification, distributor matchmaking, CEO panels, and U.S. market forecasting post-reimbursement. If you're in commercial, BD, or on the investor side, this is the room in May.
June 12–14 | Chennai, India Chennai Advanced Diabetic Foot & Wounds Conference (ADFWC) Third annual, hosted by the Diabetic Foot Society of India. Theme: "From Evidence to Excellence." Growing Indian market; worth tracking as Asia-Pacific clinical adoption of advanced wound care accelerates.
August 6–9 | Nashville, TN APMA Annual Scientific Meeting — Gaylord Opryland The national gathering for podiatric medicine. Four days. Essential for anyone selling into or tracking the podiatric channel.
September 10–11 | New Orleans, LA 🔥 IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton Third annual. Three tracks: tissue repair breakthroughs, post-acute and mobile wound care, and CAMPs market dynamics. Launch of the International Journal of Tissue Repair planned as part of the event. The post-acute and mobile wound care community's primary gathering.
October 22–24 | Anaheim, CA DFCon 2026 — JW Marriott Anaheim Resort ALPS's global interdisciplinary diabetic foot conference. First-look venue for next-generation endovascular therapies, AI diagnostics, and regenerative biologics.
December 9–12 | Phoenix, AZ Desert Foot Multi-Disciplinary Limb Salvage & Wound Care Conference — Sheraton Phoenix Downtown The flagship annual limb salvage conference. Federal service, VA, DOD, private sector, and podiatric residency communities. Strong hands-on workshop format.
Below The Knee | belowtheknee.co Independent market intelligence for wound care, limb salvage, and foot & ankle. Not subscribed yet? → [Subscribe here] Forward this to one person in your network who works in this space.
See you next week. — Scott